Sotera Health reported Q3 2026 earnings of $0.29 per share, beating consensus estimates of $0.27, with revenues of $324.89 million also exceeding expectations. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. The stock has underperformed the S&P 500 year-to-date, gaining only 0.6% versus the market's 10.2% gain.
SHC
Sotera Health CompanyAbout SHC
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
News
1 latestHeadlines open the publisher's site.